Why PTHS was halted on Oct 30 2026: definitive merger
PTHS-3.2%on Fri Oct 30 2026
Pelthos Therapeutics Inc. was down 3.2% on the day at $16.01, ranked #164 on 9.3× its usual five-minute volume, when TapeRank recorded this trading halt at 09:35 ET during regular hours when it was halted.
THE DAY ON THE LIST · 1 EVENT
- 09:35 ETHALT · REGULAR
HALTED AT $16.01 · ▼ 3.2% ON THE DAY · 9.3× 5M RVOL · RANK #164
JUSTIFIEDCONFIDENCE5/5Pelthos is up 20.1% after announcing a definitive merger with Castle Creek Biosciences, whose stockholders will receive 5.2 million Pelthos shares. The transaction offers a substantive strategic combination, while the share issuance creates dilution exposure into the move.
WHYA 20.1% pre-market move is substantial but proportionate to a definitive business combination adding a late-stage gene-therapy platform; the 5.2 million share issuance also supports a dilution-risk flag.ANALYZED 09:19 ET · 15 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 09:35 ET
LAST16.01DAY▼ 3.2%5 MIN▼ 21.40%5M RVOL9.3×5M $VOL$101KFLOAT*3.8MRANK#164SESSIONREGULARVWAP18.89HOD21.39LOD16.01OR HIGH20.50OR LOW16.01PREV CLOSE16.54PM HIGH21.39PM LOW17.09GAP▲ 13.18%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
THE SESSION
- 09:30 ETOpened at $18.72, +13.2% on the previous close of $16.54
- 09:30 ETRegular-session high, $20.50
- 09:34 ETHalted (M); resumed 09:39 ET, after 5 minutes
- 11:55 ETRegular-session low, $9.02
- 15:59 ETLast trade of the regular session, $9.35, -43.5% on the previous close of $16.54
- Volume: 224K shares in regular hours, 7K before the open
PTHS opened at $18.72 and briefly reached $20.50 after Pelthos announced a definitive merger with Castle Creek Biosciences, whose stockholders would receive 5.2 million Pelthos shares. TapeRank read the move as justified by the strategic combination and late-stage gene-therapy platform, while flagging dilution exposure from the share issuance; the stock then fell to $9.02 by 11:55 ET after a five-minute halt beginning at 09:34 ET, and finished the regular session at $9.35. A post-session halt was recorded afterward.
WRITTEN FRI OCT 30 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 09:17 ET8-K — Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation; Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders; Departure or Election of Directors or Officers; Amendments to Articles of Incorporation or Bylaws; Regulation FD Disclosure; Financial Statements and ExhibitsSEC 8-K
- 09:16 ETPelthos Therapeutics Strikes Business Combination Agreement With Castle Creek Biosciences; Shareholders Of Castle Creek Biosciences To Receive 5.2M Common Shares Of PelthosBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list